PMV Pharmaceuticals, Inc.
- Biotech or pharma, therapeutic R&D
PMV Pharma is pioneering the discovery and development of small molecule therapeutics that selectively target mutant p53. We have leveraged more than four decades of research experience and developed unique insights into p53 since its discovery in 1979 by PMV co-founder, Dr. Arnold Levine. One of the biggest challenges in moving from discovery to therapeutic application has been the complexity of p53 and the extraordinary diversity of p53 mutations in the DNA-binding domain of the protein (Levine 2019).
PMV Pharma takes a unique approach to restoring mutant p53 by physically correcting the precise geometry of the protein, thereby reactivating its tumor suppressor function. We are leveraging our precision oncology platform to design and develop a pipeline of selective, small molecule, tumor-agnostic therapies that structurally correct specific mutant p53 proteins to restore their wild-type function.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}